Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care

J Infect Dis. 2020 Feb 3;221(4):498-500. doi: 10.1093/infdis/jiz482.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Atazanavir Sulfate
  • Cardiovascular Diseases*
  • Case-Control Studies
  • Darunavir
  • HIV
  • HIV Infections*
  • HIV Protease Inhibitors*
  • Humans
  • Myocardial Infarction*
  • Risk Factors

Substances

  • HIV Protease Inhibitors
  • Atazanavir Sulfate
  • Darunavir